公开(公告)号：US10273281B2

公开(公告)日：2019-04-30

申请号：US15340238

申请日：2016-11-01

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K16/00 ,  C07K16/28 ,  A61K38/00

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US11098103B2

公开(公告)日：2021-08-24

申请号：US16354689

申请日：2019-03-15

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K16/00 ,  C07K16/28 ,  A61K38/00

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US20170145071A1

公开(公告)日：2017-05-25

申请号：US15340238

申请日：2016-11-01

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  C07K16/28 ,  C07K16/00 ,  A61K45/06

CPC classification number: C07K14/70532 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/41 ,  C07K2319/03 ,  C07K2319/30

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.